Switching from Zoledronate to Denosumab

Rationale for Switching

• Both zoledronate and denosumab are effective bone-targeting agents recommended for patients with bone metastases, according to the European Society for Medical Oncology 1
• Switching between these agents may be considered throughout the course of disease management, as stated by the European Society for Medical Oncology 1
• Denosumab may be preferred in patients with renal impairment, as suggested by the European Society for Medical Oncology 1

Important Considerations When Switching

• Denosumab should be administered every 4 weeks for treatment of bone metastases, as recommended by the European Society for Medical Oncology 1
• The National Comprehensive Cancer Network recommends calcium supplementation and vitamin D3 supplementation during denosumab therapy 3
• Correction of any vitamin D deficiency before starting denosumab is essential, according to the European Society for Medical Oncology 2

Critical Warning: Rebound Effect After Discontinuation

• If denosumab is discontinued for more than 6 months, bisphosphonate treatment is recommended to suppress rebound osteolysis, as stated by the European Society for Medical Oncology 1, 4
• Denosumab discontinuation without follow-up therapy can lead to rapid bone loss and increased fracture risk, according to the European Society for Medical Oncology 2